Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific

Zhihai Li1, Daning Wang2, Ying Gu1,2

  • 1State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen, China.

Mbio
|September 28, 2017
PubMed

Insights

This study reveals key structural details of human papillomavirus (HPV) infection and type specificity. Understanding these molecular determinants can aid in developing new therapies against HPV-related cancers.

Area of Science:

  • Virology
  • Structural Biology
  • Immunology

Background:

  • Persistent high-risk human papillomavirus (HPV) infection is a primary cause of cervical cancer.
  • Understanding HPV infection mechanisms and type specificity is crucial for developing effective therapies.
  • Lack of high-resolution structural data has hindered detailed analysis of HPV neutralization.

Purpose of the Study:

  • To elucidate the molecular basis of HPV type specificity and infection mechanisms.
  • To characterize the binding of neutralizing antibodies to HPV capsid proteins.
  • To identify key residues in HPV L1 protein critical for infectivity and antibody recognition.

Main Methods:

  • Determined crystal structures of HPV-L1 proteins bound to neutralizing antibodies (A12A3 and 28F10).
  • Utilized structure-based mutagenesis to identify critical residues for HPV infection and antibody binding.
  • Analyzed antibody binding stoichiometries and epitope mapping.

Main Results:

  • Two distinct antibody binding stoichiometries were observed for HPV58 and HPV59.
  • Identified specific residues in HPV L1 loops (DE for HPV58, FG for HPV59) as critical epitopes.
  • Demonstrated that altering these residues can redirect antibody binding specificity, highlighting their role in infectivity and type specificity.

Conclusions:

  • Provided molecular insights into structural determinants governing HPV infectivity and type specificity.
  • The findings offer a foundation for designing targeted therapeutics against neutralization-sensitive sites on HPV.
  • Understanding these interactions is key to unraveling HPV infection processes.